Teva lacks direct patient-finding infrastructure (unlike competitor Neurocrine's DTC campaigns)
Economic Opportunity
Market
Addressable Undiagnosed
1% Penetration
5% Penetration
USA
146,200-194,300
$5.3M-$7.1M/year
$26.7M-$35.4M/year
DACH
~8,330
$336K/year
$1.7M/year
Rest of World
~33,700
$1.2M/year
$5.9M/year
GLOBAL TOTAL
~188,000
$6.8M/year
$43.0M/year
Pitch Hook
"Teva, your AUSTEDO franchise is constrained by a 60% undiagnosed tardive dyskinesia rate that costs you $800M in annual revenue. While psychiatrists identify TD in only 1% of their antipsychotic patients, Ada's AI assessment reaches the 145,000+ undiagnosed US patients with involuntary movements before they see a specialist. For 8% of your first-year revenue per patient found, we navigate them from symptom check to AIMS screening to AUSTEDO prescription—turning your diagnostic gap into market expansion. With Ingrezza dominating awareness campaigns, you need systematic patient identification at scale. Let's discuss piloting Patient Finder with 10 high-volume psychiatric practices."
Timing for Ada: Engage 2026-2027 as Phase 3 data reads out, position as pre-launch partner
Economic Opportunity (Post-Approval)
Market
Addressable Undiagnosed
1% Penetration
5% Penetration
USA
12,000-23,000
$510K-$978K/year
$2.6M-$4.9M/year
DACH
~2,000-3,000
$76K-$114K/year
$380K-$570K/year
Rest of World
~15,000-20,000
$525K-$700K/year
$2.6M-$3.5M/year
GLOBAL TOTAL
~29,000-46,000
$1.1M-$1.8M/year
$5.6M-$9.0M/year
Pitch Hook (for 2026-2027)
"Teva and Sanofi, duvakitug's best-in-class potential is limited by IBD's 1-2 year diagnostic delay. The 240,000 undiagnosed Americans with moderate-severe IBD are cycling through IBS treatments while you prepare for launch. Ada's GI symptom assessment identifies these patients now—triaging bloody diarrhea + chronic pain to gastroenterology, accelerating diagnosis, and ensuring your anti-TL1A captures them as biologic-naive first-line patients. For 10% of first-year revenue per patient found, we build your launch pipeline before competitors even file. Let's discuss pre-launch partnership terms as Phase 3 data reads out."
Indication: Schizophrenia, Bipolar I Disorder (Maintenance) Class: Long-Acting Injectable Atypical Antipsychotic Status: Marketed (FDA approval April 2023), Bipolar indication added January 2025
TIER 2 - PURSUE (Bundle with AUSTEDO)
Fit Score
5.0/10
Ada Revenue Opportunity (5%)
$735K-$1.1M/year
Company Motivation
6/10
Market Numbers - USA
Schizophrenia Prevalence
2.5M current (1.2%), 3.7M lifetime
Undiagnosed Schizophrenia
250,000-375,000 (10-15%)
Drug-Addressable Undiagnosed
10,500-15,750 patients (LAI-appropriate subset)
Typical WAC
$26,400/year (75mg monthly dosing)
Net Revenue per Patient
$14,000/year (40-50% rebates)
Patient Finder Fee (10%)
$1,400 per patient found
Estimated 2024 Revenue
$50-100M (early launch phase)
Clinical Profile & Challenges
Diagnostic Delay: 1-2 years from first psychotic symptom to diagnosis
Ada Detection Challenge: 4/10 - Patients with active psychosis have poor insight, unlikely to self-assess; family/caregiver interface more valuable
UZEDY Positioning: Maintenance therapy (not first-line acute); diagnosis typically happens during ER/inpatient crisis
PF Attribution: Indirect - Ada identifies schizophrenia patients, UZEDY is downstream choice after oral stabilization
Treatment Duration: Lifelong maintenance
Advantage: Subcutaneous (not IM), monthly/bi-monthly dosing, no loading dose
Strategic Signals
UZEDY part of Teva's CNS growth portfolio
Real-world data shows better persistence vs. oral antipsychotics, fewer hospitalizations
Moderate investment appetite (6/10) - lifecycle management with bipolar expansion
Best approach: Bundle with AUSTEDO for psychiatric practice integration (both TD and schizophrenia patients seen in same settings)
Pitch Hook
"Teva, 250,000 Americans live with undiagnosed schizophrenia, losing years to untreated psychosis while you compete for the maintenance LAI market. Ada's family-facing symptom assessment detects early psychosis in at-risk individuals—before the first hospitalization—positioning UZEDY as the adherence-protecting maintenance therapy from day one. For $1,400 per patient found, we navigate families through the diagnostic process and ensure your schizophrenia portfolio (UZEDY + future pipeline) captures these patients early. Let's pilot with first-episode psychosis clinics and community mental health centers where early intervention is critical."
4. AJOVY (Fremanezumab-vfrm)
Indication: Migraine Prevention (Episodic and Chronic Migraine) Class: CGRP Monoclonal Antibody Status: Marketed (FDA approval September 2018)
TIER 3 - OPPORTUNISTIC ONLY
Fit Score
5.5/10
Ada Revenue Opportunity (5%)
$3.4M-$4.1M/year
Company Motivation
3/10
Key Challenge: Low Teva Investment Appetite
AJOVY is 3rd-tier CGRP (behind Aimovig, Emgality)
Teva provides no specific revenue disclosure or earnings focus
Estimated 2024 revenue: $100-200M globally (<5% of CGRP market)
Competitive pressure from market leaders and oral CGRPs (Nurtec, Ubrelvy)
Teva investment appetite: 4/10 - Not a strategic priority
Clinical Fit vs. Commercial Reality
Clinical Fit
Ada can identify chronic migraine (7/10 detection capability)
Market Opportunity
113,000-136,000 addressable undiagnosed USA
BUT: Company Priority
AJOVY not featured in Teva earnings; no patient-finding initiatives
Recommendation
Pursue only if bundled with AUSTEDO partnership or Teva proactively approaches
5. COPAXONE (Glatiramer Acetate)
Indication: Relapsing Forms of Multiple Sclerosis Class: Immunomodulator Status: Marketed (1996 approval), Facing Generic Erosion
NOT SUITABLE FOR PATIENT FINDER
Fit Score
2.5/10
Company Motivation
1/10
Why NOT Suitable
MS is NOT significantly underdiagnosed: Modern MRI diagnostics enable early diagnosis; <5% undiagnosed
Generic competition: Branded COPAXONE has <10% of glatiramer acetate market; most patients use generics
Declining revenue: $500M in 2024 (down 23% YoY from $590M), peak was >$4B (2012-2015)
Superior alternatives: Newer DMTs (Ocrevus, Tysabri, Gilenya) offer better efficacy
Teva investment appetite: 1/10 - Managed for cash, not growth; no R&D investment
Drug-addressable undiagnosed: Only ~1,500-2,000 patients (most would choose generic or other DMTs)
Recommendation: Do not pursue COPAXONE. If Teva develops future MS pipeline assets, revisit.
6. Olanzapine LAI (TEV-749) - PIPELINE ASSET
Indication: Schizophrenia Class: Long-Acting Injectable Atypical Antipsychotic Status: Phase 3 Completed, NDA Under FDA Review
TIER 3 - OPPORTUNISTIC (Pre-Launch)
Fit Score
5.5/10
Expected Approval
2026
Company Motivation
7/10
Key Advantage
No PDSS risk: First long-acting olanzapine without Post-Injection Delirium/Sedation Syndrome
Eliminates 3-hour post-injection monitoring requirement (major advantage vs. Zyprexa Relprevv)
Subcutaneous, once-monthly dosing
Phase 3 data: 3,470 injections, no PDSS events, consistent efficacy
Market Opportunity
Addressable
Same as UZEDY: 10,500-15,750 undiagnosed schizophrenia
Expected Peak Revenue
$400-600M (larger than UZEDY due to olanzapine's popularity)
Partnership Timing
Engage late 2026 as approval approaches for 2027 launch
Note: Same Ada detection challenges as UZEDY (schizophrenia symptoms difficult in self-assessment). Position as launch partner focused on family/caregiver pathways.